Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merrimack Pharmaceuticals has taken over the development and commercialization rights of MM-398 (aka PEP02), a stable nanoliposomal formulation of irinotecan from PharmaEngine in Europe and Asia, under an agreement signed between the companies.
Subscribe to our email newsletter
Originally developed by Hermes BioSciences, MM-398, was acquired by Merrimack in 2009.
The tie up allows Merrimack to develop and commercialize MM-398 in all territories of the world except Taiwan.
Under the terms of the agreement, Merrimack and PharmaEngine will collaborate on the development of MM-398.
Merrimack is responsible to pay a sum of $10m as an upfront payment to PharmaEngine in addition to $210m upon achievement of certain development, regulatory and sales milestones as well as tiered royalties on sales of MM-398 in Europe and Asia.
Merrimack president and CEO Robert Mulroy said they believe that unifying the development strategy of MM-398 is critical as they plan to move the program forward into late stage clinical trials in indications like gemcitabine-refractory pancreatic cancer where patients have very limited options.